Keytruda patent risk puts Merck (MRK) restructuring in focus

Merck (MRK) is splitting its human health business into two units, Oncology and Specialty, Pharma & Infectious Diseases, as it prepares for Keytruda’s expected 2028 patent expiry and potential biosimilar competition.

The move creates a dedicated home for cancer drugs such as Keytruda, while vaccines and non oncology treatments like Gardasil and ENFLONSIA are placed in a separate unit with their own leadership and priorities.

Merck’s restructuring headlines come on the back of a strong stretch for investors, with a 30 day share price return of 14.02% and a 1 year total shareholder return of 42.16%. This suggests momentum has been building as the market reacts to pipeline updates, new product approvals and the clearer separation of oncology from the rest of the human health portfolio.

If news around Keytruda and Merck’s pipeline has you thinking about where else growth stories might emerge, it could be worth scanning our list of 30 healthcare AI stocks for more potential ideas in healthcare.

With Merck shares up 14.02% over 30 days and 42.16% over the past year, yet trading at about a 3% discount to the average analyst target and a 42% intrinsic discount, is there still an opening here, or is the market already pricing in future growth?

Most Popular Narrative: 8.8% Overvalued

According to the most followed narrative from user bucailei, Merck’s fair value sits at $112.55, below the recent close at $122.46. This frames a more cautious valuation gap.

Merck & Co. presents a compelling long-term investment case, underpinned by its innovative capacity and strong market position. The current valuation, considering both quantitative metrics and qualitative factors, suggests an attractive entry point for investors willing to weather near-term volatility.

Curious what sits underneath that fair value call? The narrative leans heavily on oncology strength, resilient margins and a forward earnings multiple that assumes continued R&D payoffs. Want to see which growth and profitability assumptions are doing the heavy lifting, and how they square with the Keytruda patent overhang?

Result: Fair Value of $112.55 (OVERVALUED)

However, shifts in Keytruda’s patent outlook or any regulatory setbacks on key drugs could quickly challenge this overvaluation case and reset expectations.

Another View: Market Ratios Point to Value

Our DCF model suggests Merck at $122.46 is trading well below an estimated future cash flow value of $210.90, which flags the shares as undervalued. That is very different to the $112.55 fair value from the most popular narrative. Which lens do you trust more when patents are in play?

Next Steps

With mixed signals on value and patent risk in play, this is a moment to move quickly and check the numbers for yourself. You can start with 5 key rewards and 2 important warning signs.

Ready for more investment ideas?

If this Merck story has you thinking harder about your portfolio, do not stop here. Widen your search now and give yourself more options to compare.

• Target resilient cash generators by scanning our 53 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Prioritise income potential with 15 dividend fortresses, a curated set of companies offering higher yields for investors who want their capital working and paying them back regularly.
• Reduce portfolio stress by checking 80 resilient stocks with low risk scores, a collection of businesses with lower risk scores that can help you balance bolder positions like pharma names.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.